Ark requests re-examination of brain cancer treatment
Ark Therapeutics Group has formally requested that the European Medicines Agency re-examines its marketing authorisation application for its gene-based therapy for operable malignant glioma (brain cancer).

First Patient Treated with BioInvent's Multiple Myeloma Drug

BioInvent International AB has announced that the first patient has been treated in an open, dose-escalation Phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma. The Phase I study will investigate safety, pharmacokinetics and pharmacodynamics and will aim to define the optimal dose of the antibody for upcoming clinical Phase II development.

Testing Pharma Ingredients for Melamine

RSSL Pharma has developed a reliable test for melamine, which can be used, subject to validation, on a wide range of pharmaceutical matrices. The method uses highly sensitive liquid chromatography-mass spectrometry (LC-MS) to detect melamine and the related chemicals at levels of as low as 2.5 parts per million.

NicOx Submits Naproxcinod MAA to the EMEA

NicOx SA has announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis.

CRT Grants Rights for Targeting Technology to Aura

Cancer Research Technology has granted Aura Biosciences Inc. worldwide license to use its cancer-targeting peptides in delivering cancer treatments directly to the tumour. These peptides bind to a protein on the surface of the cell called integrin avb6, a protein complex that is found at high levels on many tumour cells but is absent in most normal tissues.